CHRD and neoplasm: As shown in Table 1, we identified in tumor biopsies from responding patients, decitabine-associated upregulation of antagonists of both TGF-β (chordin - CHRD, inhibin β A - INHBA,) and Hh (incontinentia pigmenti1 - IP1, patched 2 - PTCH2) pathways [18, 19].